Product Images Clopidogrel Bisulfate

Each tablet contains 97 875 mg of clopidogrel bisuifate USP equivalent 0 75 mg of clopidogrel base. The usual adult dosage information is not available. It is recommended to preserve in well-closed containers and store at 20°C-25°C (68°F-1077°F) [See USP Controlled Room Temperature]. The medicine is available in tablet form with NDC 82009-021-90, and it is advised for the pharmacist to dispense the medication guide to each patient. For more information, please visit www.quallentpharmaceuticals.com. The rest of the text seems to be a label with a lot number, expiration date, and a barcode.*

This appears to be a table or a graph that shows the effect of co-administered PPI on the active metabolite AUC (area under the curve) for different doses and types of medication. However, without further information or better quality text, it is difficult to interpret the data.*

The text appears to be a chart or graph displaying data related to the use of Placebo (+ aspirin) and Clopidogrel + aspirin in relation to cumulative event rate over a period of several months of follow-up. Without further context or information it is difficult to provide a more detailed description.*

The text seems to be presenting results of a trial comparing the effects of Placebo and Clopidogrel on mortality rates. The trial included subjects who were followed for up to 28 days, and the observed mortality rate in the Clopidogrel group was lower than in the Placebo group, with a proportional risk reduction of 7% (significant at p=0.03). However, the output contains some jumbled characters and misspelled words, making some parts of the text unclear.*

This appears to be a summary of a clinical trial evaluating the effectiveness of clopidogrel versus a placebo in reducing the risk of death, reinfarction, or stroke before first discharge. The trial involved over 2000 participants and found that clopidogrel resulted in a 9% reduction in risk compared to the placebo, with a significance level of p=0.002. The number of events in the clopidogrel group was not provided in the given text.*

This is a description of a medical event rate related to vascular health, both fatal and non-fatal. Clopidogrel is mentioned as a possible treatment or preventative measure.*